AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11134125
Drug: Estradiol therapy
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol therapy (transdermal or oral)
Trial: 3351823
Drug: Cefonicid (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefonicid (1 g preoperative dose)
Trial: 3351823
Drug: Cefoxitin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoxitin (2 g preoperative and postoperative for a total of four doses)
Trial: 21122270
Drug: Infliximab treatment
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab treatment for 6 months
Trial: 12079904
Drug: Recombinant DNA
RxNorm normalized name: Recombinant DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant DNA hepatitis B vaccine (3 doses: 2nd and 3rd doses at 1 and 6 months)
Trial: 12079904
Drug: Recombinant DNA
RxNorm normalized name: Recombinant DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant DNA hepatitis B vaccine
Trial: 2162877
Drug: Thiazide diuretic
RxNorm normalized name: Thiazide diuretic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiazide diuretic (Moduretic; Merck Sharp & Dohme)
Trial: 2162877
Drug: Beta-blocking agent
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocking agent (atenolol)
Trial: 6177804
Drug: Antiviral activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiviral activity in acute-phase sera
Trial: 17650171
Drug: Soaking in
RxNorm normalized name: magnesium sulfate
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Soaking in an alkaline peroxide solution (Bonyplus)
Trial: 17650171
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of soaking and brushing (methods 2 and 3)
Trial: 17650171
Drug: Brushing with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brushing with dentifrice (Dentu‐Creme) and soft Oral B toothbrush
Trial: 17650171
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of soaking and brushing (methods 2 and 5)
Trial: 16301884
Drug: Propofol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (1 mg/kg IV) + remifentanil (1 microg/kg)
Trial: 16301884
Drug: Propofol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (1 mg/kg IV)
Trial: 11896441
Drug: dl1520 gene
RxNorm normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: dl1520 gene therapy
Trial: 11896441
Drug: Percutaneous ethanol
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Percutaneous ethanol injection (control group)
Trial: 9790607
Drug: Assessment-driven algorithm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assessment-driven algorithm for treatment of pediatric status asthmaticus
Trial: 9790607
Drug: Unstructured standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unstructured standard treatment
Trial: 2533582
Drug: Nifedipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (10 mg s.I.)
Trial: 342627
Drug: Inactivated influenza
RxNorm normalized name: influenza, inactivated, whole virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated influenza virus vaccine (200 CCA units of influenza A/New Jersey/76 and 200 CCA units of influenza A/Victoria/75)
Trial: 9269055
Drug: Inactivated influenza
RxNorm normalized name: influenza, inactivated, whole virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated influenza virus vaccine
Trial: 31096775
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg vericiguat
Trial: 31096775
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg vericiguat
Trial: 22121861
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of antipsychotic treatment for at least 6 months
Trial: 22121861
Drug: Gradual withdrawal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gradual withdrawal of antipsychotic treatment
Trial: 12473554
Drug: Antioxidant vitamin
RxNorm normalized name: antioxidant vitamins with minerals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant vitamin C (25 mg/min; IA)
Trial: 7707809
Drug: 200 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 micrograms TRH intravenously every 12 h up to a maximum of four doses
Trial: 7707809
Drug: Placebo intravenously
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo intravenously every 12 h up to a maximum of four doses
Trial: 22006502
Drug: Topical silver
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical silver sulfadiazine (SSD) cream 1%, three times a day, 3 days a week, for 5 weeks during radiotherapy and one week thereafter
Trial: 9389807
Drug: 200 mg/d
RxNorm normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/d P vaginally
Trial: 9389807
Drug: 400 mg/d
RxNorm normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg/d P vaginally
Trial: 9389807
Drug: 100 mg/d
RxNorm normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/d P vaginally
Trial: 3229874
Drug: Acetyl-L-carnitine, 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetyl-L-carnitine, 2 g/day for three months
Trial: 23448854
Drug: Emergency medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emergency medicine residents (EM)
Trial: 21122200
Drug: Simvastatin and
RxNorm normalized name: simvastatin and ezetimibe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin and Aspirin
Trial: 18055141
Drug: Methacholine dry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methacholine dry powder inhaler (12.5 to 200 microg per metered dose)
Trial: 18055141
Drug: Methacholine solution
RxNorm normalized name: methacholine Ophthalmic Solution
DrugBank: Methacholine (DB06709)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methacholine solution
Trial: 15781524
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg single-dose extended-release epidural morphine (EREM)
Trial: 15781524
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg single-dose EREM
Trial: 15781524
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg single-dose EREM
Trial: 15781524
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg single-dose EREM
Trial: 15781524
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg standard epidural morphine sulfate (MS)
Trial: 15781524
Drug: Single-dose EREM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose EREM (all doses)
Trial: 15781524
Drug: Single-dose EREM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose EREM (15, 20, and 25 mg)
Trial: 8644802
Drug: Surgery (pars
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery (pars plana vitrectomy with C3F8 injection and face-down positioning for two weeks)
Trial: 1440484
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose heparin plus dihydroergotamine (DHE; 0.5 mg, given 8 hourly by sc injection)
Trial: 1440484
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose heparin alone (5,000 IU sodium heparin given subcutaneously [sc] 8 hourly until the seventh postoperative day)
Trial: 28419624
Drug: Reboxetine 12
RxNorm normalized name: REBOXETINE
DrugBank: Reboxetine (DB00234)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reboxetine 12 mg
Trial: 27400948
Drug: Irinotecan 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan 60 mg/m² on days 1, 8, and 15 plus cisplatin 60 mg/m² on day 1 (CPT-P group) every 4 weeks for six cycles
Trial: 27400948
Drug: Paclitaxel 175
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 175 mg/m² plus carboplatin AUC 6.0 mg/mL/min on day 1 (TC group) every 3 weeks for six cycles
Trial: 25929209
Drug: Covered implant
RxNorm normalized name: Canker Cover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Covered implant set
Trial: 25929209
Drug: Uncovered implant
RxNorm normalized name: Canker Cover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uncovered implant set
Trial: 24124358
Drug: salmeterol/fluticasone propionate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: salmeterol/fluticasone propionate (SFC) 50/250 μg twice daily
Trial: 24124358
Drug: tiotropium bromide
RxNorm normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tiotropium bromide 18 μg once daily
Trial: 24124358
Drug: TRIPLE therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRIPLE therapy (SFC twice daily and tiotropium once daily)
Trial: 20377577
Drug: Dual antiretroviral
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiretroviral therapy
Trial: 18333706
Drug: Telephone Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone Care Coordination Program (including simple 2‐click referral, proactive care coordination, medication management, and 5 follow‐up telephone calls)
Trial: 17028466
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment of patients with HELLP syndrome
Trial: 14711132
Drug: Pharmacological interventions
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmacological interventions (chemical agents)
Trial: 14711132
Drug: Behavioral/psychosocial interventions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral/psychosocial interventions (manual-guided therapy)
Trial: 14711132
Drug: Treatment services
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment services
Trial: 1581404
Drug: Intensive postconsolidation
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive postconsolidation therapy
Trial: 29419653
Drug: Naldemedine 0.2
RxNorm normalized name: naldemedine 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naldemedine 0.2 mg once daily
Trial: 17631074
Drug: Valsartan 160
RxNorm normalized name: valsartan 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 160 mg plus Simvastatin 20 mg
Trial: 17631074
Drug: Valsartan 160
RxNorm normalized name: valsartan 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 160 mg plus Simvastatin 80 mg
Trial: 16133688
Drug: ALN 5
RxNorm normalized name: ALN-AT3SC
DrugBank: Fitusiran (DB15002)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALN 5 mg once daily
Trial: 16133688
Drug: ALN 35
RxNorm normalized name: ALN-AT3SC
DrugBank: Fitusiran (DB15002)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALN 35 mg once weekly
Trial: 11845375
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 ml NaCl 0.9%)
Trial: 11845375
Drug: Quintuple prophylaxis
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quintuple prophylaxis (10 mg metoclopramide, 2.5 mg droperidol, 12.5 mg dolasetron, 62.5 mg dimenhydrinate, 8 mg dexamethasone)
Trial: 7669374
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine infusion (loading dose of 100 micrograms/kg over 30 min followed by continuous infusion at 10 micrograms/kg per hour)
Trial: 8494421
Drug: University of
RxNorm normalized name: ALCOHOL 75 mL in 100 mL TOPICAL GEL [University of Michigan]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: University of Wisconsin solution (UWS)
Trial: 6704504
Drug: Formulation A
RxNorm normalized name: meningococcal vaccine of unknown formulation and unknown serogroups
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation A and B
Trial: 26912209
Drug: Fluticasone/formoterol 500/20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone/formoterol 500/20 μg (high dose)
Trial: 26912209
Drug: Fluticasone/formoterol 100/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone/formoterol 100/10 μg (low dose)
Trial: 23344106
Drug: Dronedarone (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dronedarone (400 mg bid)
Trial: 10193670
Drug: enalapril 20
RxNorm normalized name: enalapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enalapril 20 mg alone
Trial: 10193670
Drug: enalapril 20
RxNorm normalized name: enalapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enalapril 20 mg with propranolol 80 mg
Trial: 10193670
Drug: lisinopril 20
RxNorm normalized name: lisinopril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lisinopril 20 mg alone
Trial: 10193670
Drug: lisinopril 20
RxNorm normalized name: lisinopril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lisinopril 20 mg with propranolol 80 mg
Trial: 28756267
Drug: Celecoxib 100
RxNorm normalized name: celecoxib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 100 to 200 mg twice daily
Trial: 28756267
Drug: Naproxen 375
RxNorm normalized name: naproxen 375 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 375 to 500 mg twice daily
Trial: 28756267
Drug: Ibuprofen 600
RxNorm normalized name: ibuprofen 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 600 to 800 mg thrice daily
Trial: 23114559
Drug: Intensive 12-week
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive 12-week strength-power training, twice a week, supervised by a physiotherapist
Trial: 17259833
Drug: Single-dose sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose sodium phosphate (45 mL)
Trial: 17259833
Drug: Double-dose sodium
RxNorm normalized name: nedocromil sodium Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-dose sodium phosphate (90 mL)
Trial: 15177699
Drug: rhGH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGH treatment for 3 and 6 months
Trial: 15177699
Drug: rhGH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGH treatment for 6 months
Trial: 15177699
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment for 3 and 6 months
Trial: 15177699
Drug: rhGH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGH treatment in the open-label phase
Trial: 15177699
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment in the open-label phase
Trial: 7999599
Drug: Calcipotriol ointment
RxNorm normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol ointment 50 micrograms/g twice daily
Trial: 7999599
Drug: Coal tar
RxNorm normalized name: Coal Tar
DrugBank: Coal tar (DB11082)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coal tar solution BP 15% v/w in aqueous cream applied in the evening
Trial: 7999599
Drug: Calcipotriol ointment
RxNorm normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol ointment and Coal tar solution
Trial: 3263379
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg prednisone
Trial: 26367736
Drug: Silymarin plus
RxNorm normalized name: silymarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silymarin plus vitamin E (2 tablets per day) and hypocaloric diet (1520 kcal, 52% carbohydrates, 25% lipids, 23% proteins) for 3 months
Trial: 23245336
Drug: Gemcitabine (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (1000 mg/m² on day 1) and Cisplatin (25 mg/m² on days 2 and 4) with regional hyperthermia (1 hour on days 2 and 4) biweekly for 4 months
Trial: 19673597
Drug: Dicloxacillin (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dicloxacillin (1.0 g intravenous dose, 30 min prior to operation)
Trial: 19673597
Drug: Placebo (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline infusion, 30 min prior to operation)
Trial: 12644419
Drug: 50 micro
RxNorm normalized name: Digoxin 250 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 micro g fentanyl epidurally
Trial: 12644419
Drug: 100 micro
RxNorm normalized name: Digoxin 100 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 micro g fentanyl epidurally
Trial: 10690937
Drug: GHRH 50
RxNorm normalized name: GHRH(1-44)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHRH 50 microg intravenous (IV) injection
Trial: 10690937
Drug: Porcine GAL
RxNorm normalized name: porcine gallbladder preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Porcine GAL 500 microg infusion from -10 to +30 minutes
Trial: 8456753
Drug: Hirulog 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hirulog 0.05 mg/kg intravenous bolus followed by 0.2 mg/kg/hour intravenous infusion
Trial: 8456753
Drug: Hirulog 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hirulog 0.15 mg/kg intravenous bolus followed by 0.6 mg/kg/hour intravenous infusion
Trial: 8456753
Drug: Heparin 5,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin 5,000 U intravenous bolus
Trial: 20386216
Drug: Mini-implant anchorage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mini-implant anchorage
Trial: 20386216
Drug: Molar anchorage
RxNorm normalized name: Polar Freeze
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Molar anchorage (non-implant)
Trial: 15083355
Drug: Postoperative morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative morphine sulfate plus lidocaine administered as a local spray
Trial: 8709630
Drug: Intensive chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive chemotherapy according to NOPHO AML protocols
Trial: 8709630
Drug: Allogeneic bone
RxNorm normalized name: Human allogeneic bone marrow derived osteoblastic cells
DrugBank: Human allogeneic bone marrow derived osteoblastic cells (DB17890)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allogeneic bone marrow transplantation (BMT) without prior chemotherapy
Trial: 6189439
Drug: Calcitonin, blocking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitonin, blocking agents, intravenous clomipramine, periarterial injections of local anaesthetics, local or general corticotherapy, physiotherapy, kinesitherapy
Trial: 31370896
Drug: Sodium citrate
RxNorm normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium citrate (SC - 0.5 g.kg‐1BM in capsules of 500 mg)
Trial: 28381584
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (DAPT) with aspirin + a P2Y12 inhibitor
Trial: 26390721
Drug: Chemotherapy (non-auto-HSCT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (non-auto-HSCT group)
Trial: 23958795
Drug: 0.8 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 mg/kg of alcohol
Trial: 9814091
Drug: tenoxicam 20
RxNorm normalized name: tenoxicam 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tenoxicam 20 mg daily for six weeks
Trial: 9814091
Drug: piroxicam 20
RxNorm normalized name: piroxicam 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: piroxicam 20 mg daily for six weeks
Trial: 7542109
Drug: Finasteride 5
RxNorm normalized name: finasteride 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride 5 mg daily for 6 months
Trial: 1087383
Drug: L‐5‐hydroxytryptophan (alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐5‐hydroxytryptophan (alone or in combination with carbidopa)
Trial: 30572162
Drug: Computer-assisted cognitive-behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-assisted cognitive-behavior therapy (CCBT)
Trial: 26464212
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment (79% prescribed insulin, mean total daily dose 0.41 units/kg)
Trial: 26464212
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (62% prescribed insulin, mean total daily dose 0.30 units/kg)
Trial: 23011728
Drug: Prandial insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prandial insulin
Trial: 26464212
Drug: Insulin dose
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin dose after adjustment for covariates
Trial: 23542800
Drug: Protective ventilation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protective ventilation strategy (tidal volume of 7 ml/kg ideal body weight, 10 cm H2O positive end-expiratory pressure, and recruitment maneuvers)